Accelerated approval drugs account for less than 1% of Medicaid spending, but states seek CMS approval to avoid coverage of these drugs and cut costs.
Douglas Holtz-Eakin, PhD
Advertisement
Articles by Douglas Holtz-Eakin, PhD
Advertisement
Latest Updated Articles
- Limiting Medicaid Access to Accelerated Approval Drugs: Costs and Consequences
Published: March 30th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5
